Overview of role of the immune system in the pathogenesis of inflammatory bowel disease

Advances in Experimental Medicine and Biology

Volumn 579, Issue , 2006, Pages 98-107

  MacDonald, Thomas T ^a   Monteleone, Giovanni ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; HUMANS; IMMUNITY, CELLULAR; INFLAMMATORY BOWEL DISEASES;

EID: 34249823876     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/0-387-33778-4_6     Document Type: Review

References (67)

1. James SP. Remission of Crohn's disease after human immunodeficiency virus infection. Gastroenterology 1988; 95:1667-1669.
2. Mullin GE, Lazenby AJ, Harris ML et al. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ukerative colitis. Gastroenterology 1992; 102:1620-1627.
3. Breese E, Braegger CP, Corrigan CJ et al. Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology 1993; 78:127-131.
4. Fuss IJ, Neurath M, Boirivant M et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996; 157:1261-1270.
5. Monteleone G, Biancone L, Marasco R et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 1997; 112:1169-1178.
6. Parronchi P, Romagnani P, Annunziato F et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol 1997; 150:823-832.
7. Parrello T, Monteleone G, Cucchiara S et al. Up-regulation of the IL-12 receptor beta 2 chain in Crohn's disease. J Immunol 2000; 165:7234-7239.
8. Monteleone G, Trapasso F, Parrello T et al. Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol 1999; 163:143-147.
9. Pizarro TT, Michie MH, Bentz M et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: Expression and localization in intestinal mucosal cells. J Immunol 1999; 162:6829-6835.
10. Avni O, Lee D, Macian F et al. T(H) cell differentiation is accompanied by dynamic changes in histone acetylation of cytokine genes. Nat Immunol 2002; 3:643-651.
11. Szabo SJ, Kim ST, Costa GL et al. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000; 100:655-669.
12. Mullen AC, Hutchins AS, High FA et al. Hlx is induced by and genetically interacts with T-bet to promote heritable T(H)1 gene induction. Nat Immunol 2002; 3:652-658.
13. Afkarian M, Sedy JR, Yang J et al. T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells. Nat Immunol 2002; 3:549-557.
14. Lighvani AA, Frucht DM, Jankovic D et al. T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. Proc Nad Acad Sci USA 2001; 98:15137-15142.
15. Neurath MF, Weigmann B, Finotto S et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J Exp Med 2002; 195:1129-1143.
16. Shanahan F. Crohn's disease. Lancet 2002; 359:62-69.
17. Duchmann R, Kaiser I, Hermann E et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 102:448-455.
18. Winkelstein JA, Marino MC, Johnston Jr RB et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000; 79:155-169.
19. Myrup B, Valerius NH, Mortensen PB. Treatment of enteritis in chronic granulomatous disease with granulocyte colony stimulating factor. Gut 1998; 42:127-130.
20. Ogura Y, Bonen DK, Inohara N et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411:603-606.
21. Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411:599-603.
22. Pflanz S, Timans JC, Cheung J et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002; 16:779-790.
23. Christ AD, Stevens AC, Koeppen H et al. An interleukin 12-related cytokine is up-regulated in ulcerative colitis but not in Crohn's disease. Gastroenterology 1998; 115:307-313.
24. Omata F, Birkenbach M, Matsuzaki S et al. The expression of IL-12 p40 and its homologue, Epstein-Barr virus-induced gene 3, in inflammatory bowel disease. Inflamm Bowel Dis 2001; 7:215-220.
25. Kett K, Rognum TO, Brandtzaeg P. Mucosal subclass distribution of immunoglobulin G-producing cells is different in ulcerative colitis and Crohn's disease of the colon. Gastroenterology 1987; 93:919-924.
26. Brandtzaeg P. The B cell system. Food Allergy & Intolerance. London: Bailliere Tindall, 1987; 118-155.
27. Mee AS, McLaughlin JE, Hodgson HJ et al. Chronic immune colitis in rabbits. Gut 1979; 20:1-5.
28. Halstensen TS, Mollnes TE, Garred P et al. Surface epithelium related activation of complement differs in Crohn's disease and ulcerative colitis. Gut 1992; 33:902-908.
29. Halstensen TS, Mollnes TE, Garred P et al. Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis. Gastroenterology 1990; 98:1264-1271.
30. Halstensen TS, Das KM, Brandtzaeg P. Epithelial deposits of immunoglobulin G1 and activated complement colocalise with the M(r) 40 kD putative autoantigen in ulcerative colitis. Gut 1993; 34:650-657.
31. McGiven AR, Chose T, Nairn RC. Autoantibodies in ulcerative colitis. Br Med J 1967; 2:19-23.
32. Marcussen H, Nerup J. Fluorescent anti-colon and organ-specific antibodies in ulcerative colitis. Scand J Gastroenterol 1973; 8:9-15.
33. Rutgeerts P, D'Haens G, Hiele M et al. Appendectomy protects against ulcerative colitis. Gastroenterology 1994; 106:1251-1253.
34. Shanahan F, O'Sullivan GC. Appendectomy, mucosal immunity, and colitis. Gastroenterology 1997; 112:1766-1767.
35. Okazaki K, Onodera H, Watanabe N et al. A patient with improvement of ulcerative colitis after appendectomy. Gastroenterology 2000; 119:502-506.
36. Cosnes J, Carbonnel F, Beaugerie L et al. Effects of appendectomy on the course of ulcerative colitis. Gut 2002; 51:803-807.
37. Pospisil R, Mage RG. Rabbit appendix: A site of development and selection of the B cell repertoire. Curr Top Microbiol Immunol 1998; 229:59-70.
38. Reynolds JD, Kennedy L, Peppard J et al. Ileal Peyer's patch emigrants are predominantly B cells and travel to all lymphoid tissues in sheep. Eur J Immunol 1991; 21:283-289.
39. Thoree VC, Golby SJ, Boursier L et al. Related IgA1 and IgG producing cells in blood and diseased mucosa in ulcerative colitis. Gut 2002; 51:44-50.
40. van Deventer SJ. Small therapeutic molecules for the treatment of inflammatory bowel disease. Gut 2002; 50(Suppl 3):III47-III53.
41. MacDonald TT, Pender SL. Proteolytic enzymes in inflammatory bowel disease. Inflamm Bowel Dis 1998; 4:157-164.
42. Saarialho-Kere UK, Vaalamo M, Puolakkainen P et al. Enhanced expression of matrilysin, collagenase, and stromelysin-1 in gastrointestinal ulcers. Am J Pathol 1996; 148:519-526.
43. Vaalamo M, Karjalainen-Lindsberg ML, Puolakkainen P et al. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am J Pathol 1998; 152:1005-1014.
44. Pender SL, Breese EJ, Gunther U et al. Suppression of T cell-mediated injury in human gut by interleukin 10: Role of matrix metalloproteinases. Gastroenterology 1998; 115:573-583.
45. Heuschkel RB, MacDonald TT, Monteleone G et al. Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease. Gut 2000; 47:57-62.
46. Pender SL, Tickle SP, Docherty AJ et al. A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol 1997; 158:1582-1590.
47. Monteleone G, MacDonald TT, Wathen NC et al. Enhancing lamina propria Th1 cell responses with interleukin 12 produces severe tissue injury. Gastroenterology 1999; 117:1069-1077.
48. Lukashev ME, Werb Z. ECM signalling: Orchestrating cell behaviour and misbehaviour. Trends Cell Biol 1998; 437-41.
49. Imai K, Hiramatsu A, Fukushima D et al. Degradation of decorin by matrix metalloproteinases: Identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. Biochem J 1997; 322:809-14.
50. Uria JA, Jimenez MG, Balbin M et al. Differential effects of transforming growth factor-beta on the expression of collagenase-1 and collagenase-3 in human fibroblasts. J Biol Chem 1998; 273:9769-9777.
51. Monteleone G, Kumberova A, Croft NM et al. Blocking Smad7 restores TGFβ1 signalling in chronic inflammatory bowel disease. J Clin Invest 2001; 108:601-608.
52. Lochter A, Galosy S, Muschler J et al. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol 1997; 139:1861-72.
53. Noe V, Fingleton B, Jacobs K et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 2001; 114:111-118.
54. Berx G, Cleton-Jansen AM, Nollet F et al. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 1995; 14:6107-15.
55. Roghani M, Becherer JD, Moss ML et al. Metalloprotease-disintegrin MDC9: Intracellular maturation and catalytic activity. J Biol Chem 1999; 274:3531-40.
56. Ito A, Mukaiyama A, Itoh Y et al. Degradation of interleukin 1β by matrix metalloproteinases. J Biol Chem 1996; 271:14657-60.
57. Shull MM, Ormsby I, Kier AB et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992; 359:693-699.
58. Kulkarni AB, Huh CG, Becker D et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993; 90:770-774.
59. Babyatsky MW, Rossiter G, Podolsky DK. Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology 1996; 110:975-984.
60. Attisano L, Wrana JL. Signal transduction by the TGF-beta superfamily. Science 2002; 296:1646-1647.
61. Moustakas A, Souchelnytskyi S, Heldin CH. Smad regulation in TGF-beta signal transduction. J Cell Sci 2001; 114:4359-4369.
62. Monteleone G, Mann J, Monteleone I et al. A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappa B activation in gut inflammation. J Biol Chem. 2004; 279:3925-3932.
63. Tahkalidis P et al. Microscopic colistis. J Castro Hepatol 17:236-248.
64. Lazenby AJ, Yardley JH, Giardiello FM et al. Lymphocytic ("microscopic") colitis: A comparative histopathologic study with particular reference to collagenous colitis. Hum Pathol 1989; 20:18-28.
65. Mosnier JF, Larvol L, Barge J et al. Lymphocytic and collagenous colitis: An immunohistochemical study. Am J Gastroenterol 1996; 91:709-713.
66. Gunther U, Schuppan D, Bauer M et al. Fibrogenesis and fibrolysis in collagenous colitis. Patterns of procollagen types I and IV, matrix-metalloproteinase-1 and -13, and TIMP-1 gene expression. Am J Pathol 1999; 155:493-503.
67. Miehlke S, Heymer P, Bethke B et al. Budesonide treatment for collagenous colitis: A randomized, double-bhnd, placebo-controlled, multicenter trial. Gastroenterology 2002; 123:978-984.